Annovis Bio (ANVS) Non Operating Income (2019 - 2026)
Annovis Bio (ANVS) posted Non Operating Income of $405800.0 for Q1 2026, up 416.38% sequentially from -$128263.0 in Q4 2025, and down 45.57% YoY from $745612.0 in Q1 2025.
Annovis Bio (ANVS) Non Operating Income (2019 - 2026) Analysis & Trends
Annovis Bio has reported Non Operating Income for 8 years, with the latest figure at $405800.0 in Q1 2026.
- Quarterly Non Operating Income fell 45.57% year-over-year to $405800.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $501249.0 (up 112.88% YoY) and the FY2025 annual result came in at $841061.0, down 60.04% from the prior year.
- Non Operating Income improved to $405800.0 in Q1 2026 per ANVS's latest filing, from -$128263.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $6.7 million in Q1 2024 and troughed at -$11.8 million in Q4 2023.
- A 5-year average of -$449128.0 and a median of $146655.0 in 2023 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2023 and 2024: Non Operating Income plunged 15974.03% in 2023, then jumped 2799.72% in 2024.
- Over 5 years, Non Operating Income stood at $74153.0 in 2022, then slumped by 15974.03% to -$11.8 million in 2023, then jumped by 107.39% to $870213.0 in 2024, then sank by 114.74% to -$128263.0 in 2025, then soared by 416.38% to $405800.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $405800.0, -$128263.0, and $172317.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Annovis Bio | 67.91 Mn | 67.91 Mn | - | -443,103.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 405,800.00 |
| Dec 31, 2025 | -128,263.00 |
| Sep 30, 2025 | 172,317.00 |
| Jun 30, 2025 | 51,395.00 |
| Mar 31, 2025 | 745,612.00 |
| Dec 31, 2024 | 870,213.00 |
| Sep 30, 2024 | -8.25 Mn |
| Jun 30, 2024 | 2.74 Mn |
| Mar 31, 2024 | 6.74 Mn |
| Dec 31, 2023 | -11.77 Mn |
| Sep 30, 2023 | 146,655.00 |
| Jun 30, 2023 | 222,578.00 |
| Mar 31, 2023 | 232,535.00 |
| Dec 31, 2022 | 74,153.00 |
| Sep 30, 2022 | 52,886.00 |
| Jun 30, 2022 | 36,024.00 |
| Mar 31, 2022 | 19,649.00 |
| Dec 31, 2021 | 5,450.00 |
| Sep 30, 2021 | 5,554.00 |
| Jun 30, 2021 | 9,548.00 |